Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04830046 · ClinicalTrials.gov registry record
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
A clinical trial of Multiple Myeloma and COVID-19, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 146
- Enrollment target
- 2
- Study locations
NCT04830046: Completed study of Multiple Myeloma and COVID-19, sponsored by Massachusetts General Hospital.
NCT04830046 is a study of Multiple Myeloma and COVID-19 that has completed, run by Massachusetts General Hospital. The registered enrollment target is 146 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04830046, a study of Multiple Myeloma and COVID-19, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 146 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.
Primary Outcome
The primary endpoint is the effective immune response (EIR) rate at 28 days following the second or final vaccine dose. EIR will be defined by a positive SARS-CoV-2 spike antibody index (S/C). The EIR rate will be reported along with the exact 95% confidence interval.
Conditions Studied
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2022-09-14 |
What the finished NCT04830046 record still lists
NCT04830046 is an observational study that tracks outcomes without assigning an intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (73% lower).
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT04830046 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04830046 about?
NCT04830046 is a clinical study titled "Covid-19 Vaccine Responsiveness in MM and Waldenstrom". This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.
What is the current status of trial NCT04830046?
This trial is currently completed. The enrollment target is 146 participants. The study started on 2021-04-15. Estimated completion is 2022-09-14.
What conditions does trial NCT04830046 study?
This clinical trial studies the following conditions: Multiple Myeloma, COVID-19, Waldenstrom Macroglobulinemia, Immune System Disorder.
Who is sponsoring clinical trial NCT04830046?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04830046 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04830046's enrollment target sits among peer trials
146 138th of 438 higher than 301 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI